

Blastocyst culture and transfer in clinical-assisted reproduction

The Practice Committee of the American Society for Reproductive Medicine and the Practice Committee of the Society for Assisted Reproductive Technology

Birmingham, Alabama

This Practice Committee Opinion reviews the published literature relating to the potential benefits, pitfalls, and risks of blastocyst culture. (Fertil Steril® 2008;90:S174–7. ©2008 by American Society for Reproductive Medicine.)

Growing embryos in vitro to the blastocyst stage for assisted reproduction offers several theoretical advantages over the transfer of cleavage stage embryos. These include [1] a higher implantation rate, [2] a decrease in the number of embryos transferred, [3] the opportunity to select more viable embryos for transfer, [4] better temporal synchronization between embryo and endometrium at the time of embryo transfer, and [5] a longer time in culture that provides the opportunity to perform preimplantation genetic diagnosis (PGD) when such is indicated (1–9).

Recent advances in our understanding of the dynamic physiology of early human embryos have led to the development of culture systems now capable of yielding viable blastocysts with greater consistency. Whereas most systems involve two distinct media used sequentially (1, 10, 11), others use a single medium (12, 13).

Commercially available media provide the means for any program to incorporate extended culture systems into its treatment protocols. These guidelines review the published literature relating to the potential benefits, pitfalls, and risks of blastocyst culture.

RESULTS FROM BLASTOCYST TRANSFER

It is difficult to separate the results of blastocyst transfer from the effects of different culture systems and patient populations among programs and trials. The results of an initial randomized trial comparing the pregnancy and implantation rates observed after transfer of cleavage or blastocyst-stage embryos in a good prognosis population (≥ 10 follicles ≥ 12 mm on day of hCG) revealed a higher implantation rate (fetal heart per embryo transferred) after blastocyst transfer than after cleavage-stage embryo transfer (50.5% vs. 30.1%, $P < .01$) (14). However, subsequent trials have generated conflicting results.

A meta-analysis has included 16 trials involving a total of 2,121 cycles of assisted reproductive technologies (1,068 day

2–3 transfer cycles and 1,048 day 5–7 transfer cycles) (15). Overall, no differences were observed in the clinical pregnancy rate (15 studies; odds ratio, [OR], 1.05; 95% confidence interval, [CI], 0.88–1.26) or the live birth rate (7 RCTs; OR, 1.03; 95% CI, 0.74–1.44) per randomized couple between the groups. The implantation rate for blastocysts (33%) was higher than for cleavage stage embryos (26%) but did not result in higher clinical pregnancy and live birth rates because more patients in the group randomized to extended culture had no embryos available for transfer (3.5% for day 2–3 transfer vs. 10.1% for day 5–7 transfer). Surprisingly, the overall multiple pregnancy rate (12 randomized control trials [RCTs]; OR, 0.85; 95% CI, 0.63–1.13) and miscarriage rate (10 RCTs; OR, 1.36; 95% CI, 0.91–2.02) also were not different between the two groups.

Six of the RCTs included in the meta-analysis compared outcomes in populations of young women (age 33 years and under) having a good prognosis for success. Among these, the clinical pregnancy rates achieved with blastocyst transfer were not significantly different from those achieved with cleavage stage embryo transfer (629 patients; OR, 1.06; 95% CI 0.83–1.34). However, two subsequent clinical trials conducted in similar “good prognosis” patient populations observed that blastocyst transfer yielded higher pregnancy and delivery rates than cleavage stage embryo transfer when equal numbers of embryos were transferred (16, 17). The combined data from these more recent studies and the earlier trials included in the meta-analysis support the conclusion that blastocyst transfer yields a significantly higher live birth rate (29% for day 2–3 vs. 36% for blastocysts) in “good prognosis” patient populations.

In unselected patient populations (14, 18–32) and among couples who have experienced one or more previous failed cycles (33, 34), pregnancy rates and live-birth rates after blastocyst transfer or cleavage stage embryo transfer are not significantly different.

Blastocyst transfer has been evaluated in one RCT conducted in a population of patients having no previous implantation (34). Fifty-four patients who exhibited an adequate ovarian response to gonadotropin stimulation and had three or more previous failed IVF cycles involving transfer of day

Committee Opinion

Reviewed June 2008.

Received and accepted September 5, 2006.

Reprints will not be available.

2–3 embryos were randomized to receive another cleavage stage embryo transfer or blastocyst transfer. Although the clinical pregnancy rate per retrieval was higher in those who received a blastocyst transfer (21.7% blastocyst vs. 12.9% cleavage stage), the difference did not achieve statistical significance. The implantation rate also was higher in the blastocyst transfer group (21.2% for blastocysts vs. 6% for cleavage stage embryos). However, because some women randomized to blastocyst transfer had no morula or blastocyst available for transfer (even 7 days after retrieval), the live birth rates per retrieval were not significantly different between the two groups (10.3% cleavage stage vs. 13% blastocyst).

POTENTIAL RISKS AND LIMITATIONS OF BLASTOCYST TRANSFER

There are several potential risks and limitations of blastocyst transfer. The lack of accepted criteria for predicting blastocyst development increases the risk of having no embryos to transfer despite observations of adequate development in vitro on day 2–3. There is some evidence to suggest that the numbers of blastomeres (35–37), and the degree of fragmentation observed on day 3 (38) correlate with the potential for blastocyst formation. However, the ability to produce blastocysts varies widely among patients, ranging from 0% to almost 100% (14). Consequently, the incidence of cancelled embryo transfers is significantly higher in patients randomized to extended culture (15).

Some studies in which sequential media were used and that observed high implantation rates for transferred blastocysts also have reported a high rate of dizygotic twinning (up to 50%) despite transfer of only two blastocysts. Overall, multiple pregnancy rates were not significantly different between groups receiving day 2–3 embryos or blastocysts. Among studies that have reported the incidence of high order multiple pregnancies (three or more implanted embryos), the incidence for groups receiving cleavage stage embryos or blastocysts also has not differed. An increased incidence of monozygotic twinning (ranging from 2.7% [39] to 13.2% [40, 41]), possibly relating to alterations in the zona pellucida and/or embryo hatching process during extended culture (42–44), remains a major drawback to routine blastocyst transfer for all ART patients.

Not surprisingly, patients randomized to blastocyst transfer have fewer embryos available for cryopreservation than those randomized to cleavage stage embryo transfer (15, 17). The results achieved with conventional slow-freezing methods for blastocysts have varied widely (45). Together, the lower number of surplus blastocysts available for cryopreservation (2.2 ± 2.7 blastocysts vs. 4.2 ± 4.1 day 2–3 embryos) and the lower implantation rate of thawed blastocysts might negate any benefits derived from blastocyst culture when cumulative pregnancy and delivery rates are compared (17). Vitrification, a method of rapid freezing, is an alternative to conventional slow-freeze methods having the theoretical advantage of providing better protection from cryoinjury due to the formation of intracellular ice crys-

als. Vitrification is currently under active investigation, and additional research aimed at improving and comparing different methods of blastocyst cryopreservation is clearly needed. Although the success achieved with blastocyst cryopreservation among centers has varied, those that perform extended culture also should have an established cryopreservation program for surplus blastocysts.

A number of reports have raised concerns regarding the effects that longer durations of culture may have on the risks of epigenetic mutations in offspring resulting from assisted reproduction (46–50), although other studies appear reassuring (51). The mechanisms via which culture media may influence epigenetic modifications are unknown. Certain components of the culture medium, such as the methionine concentration, have been implicated (52). Concerns about the potential risks of extended culture, particularly using media with undefined components and/or concentrations, merit careful consideration. Every effort should be made to standardize culture conditions and to evaluate the health of the children derived from embryos exposed to extended culture.

SUMMARY AND CONCLUSIONS

Current data regarding blastocyst culture and transfer support the following statements:

- Reliable criteria to identify embryos destined to develop to viable blastocysts in vitro have not been established.
- In trials with unselected populations, the transfer of blastocysts has not been shown to increase live birth rates compared with those achieved with transfer of cleavage stage embryos.
- In trials with populations of good prognosis patients (based on factors such as age, number, and quality of embryos), the transfer of blastocysts has been observed to yield higher live birth rates than those achieved with transfer of equal numbers of cleavage stage embryos.
- Cumulative live birth rates resulting from all transfers of fresh and frozen embryos derived from a single ART cycle may not be different after cleavage stage or blastocyst transfer because extended culture yields fewer surplus embryos and because the post-thaw survival rate for frozen blastocysts is lower than that for cleavage stage embryos.
- In trials with populations of poor prognosis patients (based on factors such as age, number, and quality of embryos), blastocyst transfer does not increase and may decrease live birth rates.
- Transfer of multiple blastocysts results in a high multiple pregnancy rate. Every effort should be made to perform single blastocyst transfers in good prognosis patients.
- Patients must be counseled that blastocyst culture may increase the risk of monozygotic twinning.
- Success with the cryopreservation of blastocysts varies widely among programs.

Acknowledgments: This report was developed under the direction of the Practice Committee of the Society for Assisted Reproductive Technology

and the Practice Committee of the American Society for Reproductive Medicine as a service to their members and other practicing clinicians. While this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. This report was approved by the Executive Council of the Society for Assisted Reproductive Technology and by the Board of Directors of the American Society for Reproductive Medicine.

REFERENCES

- Gardner DK, Lane M. Culture and selection of viable human blastocysts: a feasible proposition for human IVF? *Hum Reprod Update* 1997;3:367–82.
- Pool TB, Atiee SR, Martin JE. Oocyte and embryo culture: Basic concepts and recent advances. *Infert Reprod Med Clinics N Amer* 1998;9:181–203.
- Tsirigotis M. Blastocyst stage transfer: pitfalls and benefits: Too soon to abandon current practice? *Hum Reprod* 1998;13:3285–9.
- Gardner DK, Schoolcraft WB. No longer neglected: the human blastocyst. *Hum Reprod* 1998;13:3289–92.
- Desai NN. The road to blastocyst transfer. *Hum Reprod* 1998;13:3292–4.
- Quinn P. Some arguments on the pro side. *Hum Reprod* 1998;13:3294–5.
- Bavister BD, Boatman DE. The neglected human blastocyst revisited. *Hum Reprod* 1997;12:1607–10.
- Behr B. Blastocyst culture without co-culture: role of embryo metabolism. *J Assist Reprod Genet* 1997;14(Suppl):13S.
- Menezo YJ, Hamamah S, Hazout A, Dale B. Time to switch from co-culture to sequential defined media for transfer at the blastocyst stage. *Hum Reprod* 1998;13:2043–4.
- Gardner DK, Vella P, Lane M, Wagley L, Schlenker T, Schoolcraft WB. Culture and transfer of human blastocysts increases implantation rates and reduces the need for multiple embryo transfers. *Fertil Steril* 1998;69:84–8.
- Jones GM, Trounson AO, Gardner DK, Kausche A, Lolatgis N, Wood C. Evolution of a protocol for successful blastocyst development and pregnancy. *Hum Reprod* 1998;13:169–77.
- Macklon NS, Pieters MH, Hassan MA, Jeucken PH, Eijkemans MJ, Fauser BC. A prospective randomized comparison of sequential versus monoculture systems for in-vitro human blastocyst development. *Hum Reprod* 2002;17:2700–5.
- Biggers JD, Racowsky C. The development of fertilized human ova to the blastocyst stage in KSOM^(AA) medium: is a two-step protocol necessary? *Reprod Biomed Online* 2002;5:133–40.
- Gardner DK, Schoolcraft WB, Wagley L, Schlenker T, Stevens J, Hesla J. A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. *Hum Reprod* 1998;13:3434–40.
- Blake D, Proctor M, Johnson N, Olive D. Cleavage stage versus blastocyst stage embryo transfer in assisted conception (review). *Cochrane Database Syst Rev* 2005;(2):CD002118.
- Papanikolaou EG, D'haeseleer E, Verheyen G, Van de Velde H, Camus M, Steirteghem A, et al. Live birth rate is significantly higher after blastocyst transfer than after cleavage-stage embryo transfer when at least four embryos are available on day 3 of embryo culture. *Hum Reprod* 2005;20:3198–203.
- Papanikolaou EG, Camus M, Kolibianakis EM, Van Landuyt L, Van Steirteghem A, Devroey P. In vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos. *N Engl J Med* 2006;354:1139–46.
- Coskun S, Hollanders J, Al-Hassan S, Al-Sufyan H, Al-Mayman H, Jaroudi K. Day 5 versus day 3 transfer: a controlled randomized trial. *Hum Reprod* 2000;15:1947–52.
- Huisman GJ, Fauser BC, Eijkemans MJ, Pieters MH. Implantation rates after in vitro fertilization and transfer of a maximum of two embryos that have undergone three to five days of culture. *Fertil Steril* 2000;73:117–22.
- Utsunomiya T, Naitou T, Nagaki M. A prospective trial of blastocyst culture and transfer. *Hum Reprod* 2002;17:1846–51.
- Bungum M, Bungum L, Humaidan P, Yding Andersen C. Day 3 versus day 5 embryo transfer: a prospective randomized study. *Reprod Biomed Online* 2003;7:98–104.
- Frattarelli JL, Leondires MP, McKeeby JL, Miller BT, Segars JH. Blastocyst transfer decreases the multiple pregnancy rates in in vitro fertilization cycles: a randomized controlled trial. *Fertil Steril* 2003;79:228–30.
- Hreinsson J, Rosenlund B, Fridstrom M, Ek I, Levkov L, Sjoblom P, et al. Embryo transfer is equally effective at cleavage stage and blastocyst stage: a randomized prospective study. *Eur J Obstet Gynecol Reprod Biol* 2004;117:194–200.
- Levron J, Shulman A, Bider D, Seidman D, Levin T, Dor J. A prospective randomized study comparing day 3 with blastocyst-stage embryo transfer. *Fertil Steril* 2002;77:1300–1.
- Livingstone M, Bowman M. Single blastocyst transfer: a prospective randomized trial. Abstracts on the 17th World Congress on Fertility and Sterility, Melbourne, Australia, November 25–30, 2001:218.
- Rienzi I, Ubaldi F, Iacobelli M, Ferrero S, Minasi MG, Martinez F, et al. Day 3 embryo transfer with combined evaluation at the pronuclear and cleavage stages compares favorably to blastocyst transfer. *Hum Reprod* 2002;17:1852–5.
- Emiliani S, Delbaere A, Vannin A, Biramane J, Verdoodt M, Englert Y, et al. Similar delivery rates in a selected group of patients for day 2 and day 5 embryos both cultured in sequential medium: a randomized study. *Hum Reprod* 2003;18:2145–50.
- Karaki RZ, Samarraie SS, Younis NA, Lahlob TM, Ibrahim MH. Blastocyst culture and transfer: a step towards improved in vitro fertilization outcome. *Fertil Steril* 2002;77:114–8.
- Kolibianakis EM, Zikopoulos K, Verpoest W, Camus M, Joris H, Van Steirteghem AC, et al. Should we advise patients undergoing in vitro fertilization to start a cycle leading to a day 3 or a day 5 transfer? *Hum Reprod* 2004;19:2550–4.
- Motta LA, Alegretti JR, Pico M, Sousa JW, Baracat EC, Serafini P. Blastocyst vs. cleaving embryo transfer: a prospective randomized trial [abstract]. *Fertil Steril* 1998;70(Suppl 1):S17.
- Schillaci R, Castelli A, Vassiliadis A, Venezia R, Perino A, Cittadini E. Blastocyst stage versus day 2 embryo transfer in IVF. Abstracts of the 18th Annual Meeting of ESHRE, Vienna 2002:P-418.
- Van der Auwera I, Debrock S, Spiessens C, Afschrift H, Bakelants E, Meuleman C, et al. A prospective randomized study: day 2 versus day 5 embryo transfer. *Hum Reprod* 2002;17:1507–12.
- Devreker F, Delbaere A, Emiliani S, Van den Bergh M, Biramane J, Englert Y. Prospective and randomised comparison between day 2 or day 5 for patients with more than 4 IVF attempts. *ESHRE 2000, Bologna, Italy, June 25–28, 2000:P135.*
- Levitas E, Lunenfeld E, Har-Vardi I, Albotiano S, Sonin Y, Hackmon-Ram R, et al. Blastocyst-stage embryo transfer in patients who failed to conceive in three or more day 2-3 embryo transfer cycles: a prospective, randomized study. *Fertil Steril* 2004;81:567–71.
- Racowsky C, Jackson KV, Cekleniak NA, Fox JH, Hornstein MD, Ginsburg ES. The number of 8-cell embryos is a key determinant for selecting day 3 or day 5 transfer. *Fertil Steril* 2000;73:558–64.
- Langley MT, Marek DM, Gardner DK, Doody KM, Doody KJ. Extended embryo culture in human assisted reproduction. *Hum Reprod* 2001;16:902–8.
- Neuber E, Rinaudo P, Trimarchi JR, Sakkas D. Sequential assessment of individually cultured human embryos as an indicator of subsequent good embryo quality blastocyst development. *Hum Reprod* 2003;18:1307–12.
- Shoukir Y, Chardonnens D, Campana A, Bischof P, Sakkas D. The rate of development and time of transfer play different roles in influencing the viability of human blastocyst. *Hum Reprod* 1998;13:676–81.
- Rijnders PM, van Os HC, Jansen CAM. Increased incidence of monozygotic twinning following the transfer of blastocysts in human IVF/ICSI. *Fertil Steril* 1998;70:S15–6.
- Milki AA, Jun SH, Hinckley MD, Behr B, Giudice LC, Westphal LM. Incidence of monozygotic twinning with blastocyst compared to cleavage-stage transfer. *Fertil Steril* 2003;79:503–6.

41. Sheiner E, Har-Vardi I, Potashnik G. The potential association between blastocyst transfer and monozygotic twinning. *Fertil Steril* 2001;75:217–8.
42. Behr B, Fisch JD, Racowsky C, Miller K, Pool TB, Milki AA. Blastocyst-ET and monozygotic twinning. *J Assist Reprod Genet* 2000;17:349–51.
43. da Costa AL, Abdelmassih S, de Oliveira FG, Abdelmassih V, Abdelmassih R, Nagy ZP, et al. Monozygotic twins and transfer at the blastocyst stage after ICSI. *Hum Reprod* 2001;16:333–6.
44. Tarlatzis BC, Qublan HS, Sanopoulou T, Zepiridis L, Grimbizis G, Bontis J. Increase in the monozygotic twinning rate after intracytoplasmic sperm injection and blastocyst stage embryo transfer. *Fertil Steril* 2002;77:196–8.
45. Veeck LL, Bodine R, Clarke RN, Berrios R, Libraro J, Moschini RM, et al. High pregnancy rates can be achieved after freezing and thawing human blastocysts. *Fertil Steril* 82;82:1418–27.
46. Cox GF, Burger J, Lip V, Mau UA, Sperling K, Wu BL, et al. Intracytoplasmic sperm injection may increase the risk of imprinting defects. *Am J Hum Genet* 2002;71:162–4.
47. DeBaun MR, Niemitz L, Feinberg AP. Association of in vitro fertilization with Beckwith-Weidemann syndrome and epigenetic alterations of LIT1 and H19. *Am J Hum Genet* 2003;72:156–60.
48. Gicquel C, Gaston V, Mandelbaum J, Siffroi JP, Flahault A, Le Bouc YL. In vitro fertilization may increase the risk of Beckwith-Weidemann syndrome related to the abnormal imprinting of the KCNQ10T gene. *Am J Hum Genet* 2003;72:1338–41.
49. Maher ER, Brueton LA, Bowdin SC, Luharia A, Cooper W, Cole TR, et al. Beckwith-Weidemann syndrome and assisted reproductive technology (ART). *J Med Genet* 2003;40:62–4.
50. Moll AC, Imhof SM, Cruysberg JR, Schouten-van Meeteren AY, Boers M, van Leeuwen FE. Incidence of retinoblastoma in children born after in vitro fertilisation. *Lancet* 2003;36:309–10.
51. Lidegaard O, Pinborg A, Andersen AN. Imprinting diseases and IVF: Danish National IVF cohort study. *Hum Reprod* 2005;20:950–4.
52. Niemitz EL, Feinberg AP. Epigenetics and assisted reproductive technology: a call for investigation. *Am J Hum Genet* 2004;74:599–609.